Clinical Evaluation of Unani formulation in Gastritis- A Pilot Study

Abstract

Background and objectives: Gastritis is a painful or inflammatory state of the stomach and the mucosa covering it. The most common cause of gastritis is helicobacter pylorus. It is caused by certain infection, or by the routine use of antiinflammatory painkiller. Unani Physician has identified various medicinal products in classical text indicated for the treatment of gastritis. Therefore, a clinical trial was conducted to evaluate the clinical efficacy and safety of Unani Formulation in gastritis on scientific parameters. Methods: The study was designed as single blind pilot study on 12 patients of gastritis. Unani Formulation (Amla-2 part, Asl-Us-Soos-2 part, and Badiyan-2part) was given in the form of powder at the dose of 6 g twice a day after meal for the period of 28 days. All the patients of were assessed weekly on subjective parameters (at 0, 7th, 14th , 21th, and 28th day) whereas objective parameters were assessed before and after the treatment. The outcome of intervention was analyzed using appropriate statistical methods. Results: The study effects on subjective parameters like pain in abdomen, epigastric burning, nausea & vomiting and early satiety were found significantly reduced significantly. The objective parameter VAS and 5 PLS was found highly significant when compared before and after with p<0.0001. The results were analyzed after using paired ‘t’ test. Interpretation & Conclusion: The findings about the both parameters (subjective and objective) that the ‘Unani Formulation is effective gastritis and the cure was significant. Safety parameters (SGOT, SGPT, Blood Urea and Serum Creatinine) were remains unchanged. Therefore, it can be concluded that the Unani Formulation is safe and effective in management of gastritis.